- Home
- BRLT vs XCUR Comparison
BRLT vs XCUR Comparison
Compare BRLT & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | XCUR |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 17.6M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRLT | XCUR |
|---|---|---|
| Price | $1.17 | $2.89 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | ★ 65.7K | 12.3K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.11 | $2.62 |
| 52 Week High | $3.10 | $9.50 |
Technical Indicators
Market Signals| Indicator | BRLT | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 40.57 |
| Support Level | $1.11 | $2.62 |
| Resistance Level | $1.37 | $3.50 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 2.50 | 21.08 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.